Log in Free sign up

Acer Therapeutics (ACER) News and press releases

News

From Benzinga Pro

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

24 Stocks Moving in Tuesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Bird Global, Inc. (NASDAQ: BRDS) rose 26.3% to $1.24 in pre-market trading after the company posted strong Q1 sales.

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million.

Acer Therapeutics: Q1 Earnings Insights

Acer Therapeutics (NASDAQ:ACER) reported its Q1 earnings results on Monday, May 16, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Acer Therapeutics Q1 EPS $(0.64) Down From $(0.33) YoY

Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.64) per share. This is a 93.94 percent decrease over losses of $(0.33) per share from the same period last year.

Acer Therapeutics Announces Agreement With FDA On Special Protocol Assessment For Its Phase 3 EDSIVO Trial In Vascular Ehlers-Danlos Syndrome Patients

Biotech, News, FDA, General

Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022 NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition,

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

12 Health Care Stocks Moving In Monday's Pre-Market Session

Acer Therapeutics' EDSIVO (celiprolol) Granted FDA Breakthrough Therapy Designation For Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical

Acer Therapeutics Reports Enrollment Of First Patient In Its Phase 2a Trial Of ACER-801 For Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause

Biotech, News, FDA, General

Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Acer Therapeutics Q4 EPS $(0.31) Up From $(0.50) YoY

Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.31) per share. This is a 38 percent increase over losses of $(0.50) per share from the same period last year.

Press releases

From Benzinga Pro

Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update

Earnings, Press Releases

NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Health Care, Press Releases

NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

Health Care, Press Releases

NEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

News, Press Releases

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY))

Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference

News, Press Releases

NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Contracts, Press Releases

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)

SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021

Earnings, Press Releases

Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter as independent

Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities

Markets, Press Releases

NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update

Earnings, Press Releases

NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and